What do DCISionRT, Precision Medicine, PSMA PET Tech, and a New Fellow Have In Common?

What:

GenesisCare—one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom—is driving significant change in the way patients are diagnosed and treated, and we’re offering our breadth of expertise at this year's ASTRO conference. Our team of experts can speak to some of the topics below and one is being inducted as a new ASTRO fellow:

- Ground-breaking test that identifies DCIS patient risks and treatments
- Precision medicine targeting tumors without damaging healthy tissue using FDA-approved Pylarify
- Management how-to for pelvic radiotherapy survivors
- Next-generation PSMA imaging PET technology to detect prostate cancer risks

Who & Where:

Tuesday, Oct. 26 at 11:01-11:15 a.m in McCormick Place West, Room W375 - Dr. Constantine A. Mantz, MD, FASTRO is being recognized as an ASTRO Fellow, which is an individual who has made a significant contribution to the Society and field of radiation oncology through research, education, patient care and service to the field. Since 2006, only 394 of ASTRO's 10,000 global members have received the FASTRO designation and been recognized as an ASTRO Fellow.

Tuesday, Oct. 26 from 3:55-4:05 p.m. in McCormick Place West, Room W185 a/b/c/d - Dr. Frank Vicini, MD, FASTRO will present “DCIS Precision Medicine Study Results,” and how the DCISionRT® test assesses a woman's 10-year risk of DCIS recurrence while predicting the benefit from radiation therapy.

Wednesday, Oct. 27 from 8:32-8:44 p.m. in McCormick Place West, Room W184 a/b/c/d - Dr. Bridget F. Koontz, MD will present “How to Manage the Complex Needs of Pelvic Radiotherapy Survivors” with an overview of published evidence about the various toxicity types and approaches for managing them.

GenesisCare Global Chief Medical Officer Dr. Walter “Wally” J. Curran, Jr. MD, FACR, FASCO is available to discuss the latest findings and trends in oncology, including our new PSMA PET Technology for prostate cancer testing.
Dr. Vicini Quote:

“DCISionRT is an important new test to guide tailored treatment decisions for patients with DCIS based on a personalized, quantifiable score versus a one-size-fits-all approach,” said Dr. Frank Vicini. “For the first time, with DCISionRT and its response subtype we are able to identify a group of women with a poor subtype who may be at higher risk of recurrence despite surgery and standard radiation therapy. This group of women may be candidates for enhanced and/or alternative therapies.”

On-Site Interviews:

For on-site interviews during ASTRO 2021 with these accomplished GenesisCare doctors and more information about new technology, the innovative treatments we deliver through over 300 U.S. centers, and brings to over 400,000 cancer patients worldwide annually please contact Angharad Bhardwaj.

Angharad.bhardwaj@usa.genescare.com / 843-754-2378

About GenesisCare:

Dedicated to designing better patient care experiences with the best possible life outcomes, GenesisCare—the world’s largest provider of radiation oncology—recently kicked off a new investment series to strategically accelerate development and access to tools that transform the way cancers are diagnosed and treated. The company’s investment in Prelude Dx™ will fast-track the creation of reliable, accurate treatment of ductal carcinoma in situ (aka the earliest form of breast cancer.)

With growing research projects now numbering to more than 150 clinical trials, GenesisCare’s own contract research organization and global innovation programs focused on precision medicine and novel therapies, providing access to new therapies for more patients.

With a network of over 5,500 oncology experts worldwide, the Sydney, Australia-based company is dedicated to investing in the latest technologies and tools to target cancer while minimizing harmful side-effects throughout over 440 locations in the U.S., Australia, UK, and Spain.